Jaeb Center for Health Research
Quick facts
Marketed products
Phase 3 pipeline
- Bevacizumab + Deferred Aflibercept Group · Oncology
This combination uses bevacizumab (an anti-VEGF monoclonal antibody) with deferred aflibercept (a VEGF trap) to inhibit vascular endothelial growth factor signaling, reducing abnormal blood vessel formation. - Deferred aflibercept · Ophthalmology / Oncology
Aflibercept is a recombinant fusion protein that acts as a soluble decoy receptor for vascular endothelial growth factor (VEGF) and placental growth factor (PlGF), binding and neutralizing these pro-angiogenic factors. - Placebo Eyedrops · Ophthalmology
Placebo eyedrops contain no active pharmaceutical ingredient and produce therapeutic effects through the placebo effect. - Prompt aflibercept · Oncology, Ophthalmology
Aflibercept is a soluble decoy receptor that binds and neutralizes vascular endothelial growth factor (VEGF) and placental growth factor (PlGF) to inhibit angiogenesis. - Ranibizumab + deferred laser · Ophthalmology
Ranibizumab is a recombinant humanized monoclonal antibody fragment that inhibits vascular endothelial growth factor A (VEGF-A) by binding to its receptor. - Ranibizumab + laser · Ophthalmology
Ranibizumab blocks vascular endothelial growth factor (VEGF) to reduce abnormal blood vessel growth, combined with laser photocoagulation to seal leaking vessels in the retina. - Sham injection + laser · Dermatology
This drug combines a sham injection with laser therapy, which is a non-pharmacological treatment approach. - Triamcinolone Acetonide + laser · Ophthalmology
Triamcinolone acetonide is a corticosteroid that reduces inflammation, combined with laser treatment to mechanically ablate or coagulate tissue, used together to treat retinal conditions.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: